Brookline Capital Management Estimates MRKR FY2026 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Stock analysts at Brookline Capital Management issued their FY2026 earnings estimates for Marker Therapeutics in a research report issued on Monday, March 31st. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of ($5.15) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Marker Therapeutics’ FY2027 earnings at ($2.46) EPS, FY2028 earnings at $2.42 EPS and FY2029 earnings at $8.75 EPS.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Monday, March 31st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Marker Therapeutics had a negative return on equity of 89.63% and a negative net margin of 179.74%. The company had revenue of $1.22 million during the quarter, compared to analyst estimates of $5.25 million.

Several other analysts have also weighed in on MRKR. WBB Securities reiterated a “strong-buy” rating and issued a $12.50 target price on shares of Marker Therapeutics in a research note on Tuesday. Canaccord Genuity Group started coverage on shares of Marker Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $8.00 price objective for the company.

Marker Therapeutics Price Performance

Shares of NASDAQ:MRKR opened at $1.20 on Wednesday. Marker Therapeutics has a 1-year low of $1.10 and a 1-year high of $5.99. The business’s 50 day moving average is $1.57 and its 200-day moving average is $2.70.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. NEA Management Company LLC boosted its position in Marker Therapeutics by 51.7% during the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after buying an additional 554,250 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Marker Therapeutics in the 4th quarter valued at about $2,847,000. Blue Owl Capital Holdings LP acquired a new stake in Marker Therapeutics during the fourth quarter worth approximately $1,724,000. Aisling Capital Management LP lifted its position in shares of Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after acquiring an additional 11,084 shares during the period. Finally, LPL Financial LLC bought a new stake in Marker Therapeutics in the fourth quarter valued at $248,000. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.